CD274 and urinary bladder cancer: Given the fact that there is a universal lack of predictive biomarkers for immunotherapy, we suggest the possibility of stratifying patients into likely-responders and likely-not-responders to anti-PD-L1 therapy, based on their bladder cancer molecular subtypes.